April 12, 2018 / 11:58 AM / 7 months ago

BRIEF-Aeglea Biotherapeutics Presents Trial Data Showing Treatment Effects In Arginase 1 Deficiency Patients

April 12 (Reuters) - Aeglea Bio Therapeutics Inc:

* AEGLEA BIOTHERAPEUTICS PRESENTS NEW PHASE 1/2 TRIAL DATA DEMONSTRATING CLINICALLY RELEVANT TREATMENT EFFECTS IN ARGINASE 1 DEFICIENCY PATIENTS AT THE 2018 ACMG ANNUAL CLINICAL GENETICS MEETING

* NEW DATA LINKS ARGININE REDUCTION TO MEANINGFUL CLINICAL EFFECTS IN FIRST TWO PATIENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below